No products in the cart.
Pre-made Inebilizumab benchmark antibody ( Whole mAb, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-273
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.
| Products Name (INN Index) | Pre-Made Inebilizumab biosimilar, Whole mAb, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody |
|---|---|
| INN Name | Inebilizumab |
| Target | CD19 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Cellective Therapeutics,MedImmune |
| Conditions Approved | Neuromyelitis optica |
| Conditions Active | Autoimmune disorders,Myasthenia gravis,Renal transplant rejection |
| Conditions Discontinued | B-cell lymphoma,Chronic lymphocytic leukaemia,Diffuse large B-cell lymphoma,Follicular lymphoma,Multiple myeloma,Multiple sclerosis,Systemic scleroderma |
| Development Tech | POTELLIGENT Technology |
| Previous Name | NA |
| Gm Offical Target Name | CD19 |
| Package |
Previous slide
Next slide
